ConductScience.org, home

Comparison · NCT00448669-sae

TDF-FTC, Condoms, Risk Counseling vs Placebo, Condoms, Risk Counseling: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. TDF-FTC, Condoms, Risk Counseling vs Placebo, Condoms, Risk Counseling: serious adverse events. Trial comparisons, record NCT00448669-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00448669-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.06870.05130.0916wilson
Risk in group 20.07240.05430.0958wilson
Risk difference, group 1 minus group 2-0.00363-0.03280.0255newcombe hybrid score
Risk ratio, group 1 over group 20.950.6321.43log
Odds ratio, group 1 over group 20.9460.611.47log
Number needed to treat, for one fewer participant with a serious adverse event on TDF-FTC, Condoms, Risk Counseling than on Placebo, Condoms, Risk Counseling276from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TDF-FTC, Condoms, Risk Counseling
Participants randomized to the active arm received daily oral TDF-FTC along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.~Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg: Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.
42611EG000
Group 2Placebo, Condoms, Risk Counseling
Participants randomized to the placebo arm received a daily oral placebo tablet along with male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.~TDF-FTC placebo: Placebo comparator for TDF-FTC
44608EG001

Harm

What it counts
Total, serious adverse events
Time frame
Adverse event data were collected throughout the course of the study until study completion, i.e. up to 3 years.

Source ClinicalTrials.gov

Trial

Title
Botswana TDF/FTC Oral HIV Prophylaxis Trial
NCT number
NCT00448669
Phases
PHASE2, PHASE3
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Lead sponsor
Centers for Disease Control and Prevention
Results first posted
2020-02-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00448669-sae